CAM-101 not checked

Cambium Bio Limited · FD hPL 10% vol/vol · FD hPL 30% vol/vol

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
1 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Dry Eye Disease, Dry Eye, Dry Eyes Chronic, Dry Eye Syndromes
Main trialPhase 3
“Prospective, multicenter, randomized, vehicle-controlled, double-masked, study of CAM-101 topical ophthalmic solution compared to vehicle control followed by crossover to long-term follow-up open-label treatment with CAM-101 for one year.”In the company’s words, NCT06903611 on ClinicalTrials.gov
Other names
Elate Ocular · FD hPL · FD hPL 10% vol/vol · FD hPL 30% vol/vol

Other drugs for Dry Eye Disease

All 44 drugs for Dry Eye Disease

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting 30 Nov 2027 Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry Eye
Phase 1/2Completed 12 Dec 2019 Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow CAM-101

Following is part of Solo: you see every change to CAM-101 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in